- Home
- GALT vs MDBH Comparison
GALT vs MDBH Comparison
Compare GALT & MDBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- MDBH
- Stock Information
- Founded
- GALT 2000
- MDBH 1997
- Country
- GALT United States
- MDBH United States
- Employees
- GALT N/A
- MDBH N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- MDBH
- Sector
- GALT Health Care
- MDBH
- Exchange
- GALT Nasdaq
- MDBH Nasdaq
- Market Cap
- GALT 147.8M
- MDBH 66.8M
- IPO Year
- GALT N/A
- MDBH 2023
- Fundamental
- Price
- GALT $1.04
- MDBH $6.34
- Analyst Decision
- GALT Strong Buy
- MDBH
- Analyst Count
- GALT 1
- MDBH 0
- Target Price
- GALT $11.00
- MDBH N/A
- AVG Volume (30 Days)
- GALT 1.1M
- MDBH 9.9K
- Earning Date
- GALT 11-13-2024
- MDBH 11-12-2024
- Dividend Yield
- GALT N/A
- MDBH N/A
- EPS Growth
- GALT N/A
- MDBH N/A
- EPS
- GALT N/A
- MDBH N/A
- Revenue
- GALT N/A
- MDBH $1,937,885.00
- Revenue This Year
- GALT N/A
- MDBH N/A
- Revenue Next Year
- GALT N/A
- MDBH N/A
- P/E Ratio
- GALT N/A
- MDBH N/A
- Revenue Growth
- GALT N/A
- MDBH N/A
- 52 Week Low
- GALT $0.73
- MDBH $5.78
- 52 Week High
- GALT $4.27
- MDBH $13.25
- Technical
- Relative Strength Index (RSI)
- GALT 20.80
- MDBH 44.04
- Support Level
- GALT $1.80
- MDBH $6.00
- Resistance Level
- GALT $2.36
- MDBH $6.27
- Average True Range (ATR)
- GALT 0.27
- MDBH 0.25
- MACD
- GALT -0.08
- MDBH -0.06
- Stochastic Oscillator
- GALT 15.07
- MDBH 33.03
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About MDBH MDB Capital Holdings LLC common
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.